Literature DB >> 9799710

The complement system and adaptive immunity.

D T Fearon1.   

Abstract

The complement system covalently attaches C3d to microbial antigens which binds to CR2 on B lymphocytes, leading to a markedly enhanced adaptive immune response to that antigen. The enhancement is mediated by the cross-linking of the CR2-CD19 complex to mIg which augments the activation of several intracellular signalling pathways. Two additional receptors of the B lymphocyte, FcgammaRIIB and CD22, have opposing effects when cross-linked to mIg, the former suppressing signalling by recruiting the inositol phosphatase, SHIP, and the latter by activating the phosphotyrosine phosphatase, SHP-1. Two principles emerge from these studies: innate immunity guides the adaptive immune response, and activation of the B lymphocyte is determined by co-receptors which evaluate the biological characteristics of antigen. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9799710     DOI: 10.1006/smim.1998.0137

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  22 in total

1.  C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge.

Authors:  T M Ross; Y Xu; R A Bright; H L Robinson
Journal:  Nat Immunol       Date:  2000-08       Impact factor: 25.606

2.  Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins.

Authors:  T M Ross; Y Xu; T D Green; D C Montefiori; H L Robinson
Journal:  AIDS Res Hum Retroviruses       Date:  2001-06-10       Impact factor: 2.205

3.  Matrix metalloproteinase activity creates pro-angiogenic environment in primary human retinal pigment epithelial cells exposed to complement.

Authors:  Mausumi Bandyopadhyay; Bärbel Rohrer
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-04-18       Impact factor: 4.799

Review 4.  Molecular structure and expression of anthropic, ovine, and murine forms of complement receptor type 2.

Authors:  Dong Liu; Jian-Ying Zhu; Zhong-Xiang Niu
Journal:  Clin Vaccine Immunol       Date:  2008-04-09

5.  Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases.

Authors:  Masha Fridkis-Hareli; Michael Storek; Istvan Mazsaroff; Antonio M Risitano; Ante S Lundberg; Christopher J Horvath; V Michael Holers
Journal:  Blood       Date:  2011-08-22       Impact factor: 22.113

6.  Sublytic membrane-attack-complex (MAC) activation alters regulated rather than constitutive vascular endothelial growth factor (VEGF) secretion in retinal pigment epithelium monolayers.

Authors:  Kannan Kunchithapautham; Bärbel Rohrer
Journal:  J Biol Chem       Date:  2011-05-12       Impact factor: 5.157

7.  Complement and dilated cardiomyopathy: a role of sublytic terminal complement complex-induced tumor necrosis factor-alpha synthesis in cardiac myocytes.

Authors:  Thomas P Zwaka; Dimitar Manolov; Cüneyt Ozdemir; Nikolaus Marx; Ziya Kaya; Matthias Kochs; Martin Höher; Vinzenz Hombach; Jan Torzewski
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

8.  Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.

Authors:  Joseph F Bower; Xinzhen Yang; Joseph Sodroski; Ted M Ross
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

Review 9.  Herpes simplex virus as a tool to define the role of complement in the immune response to peripheral infection.

Authors:  Mark A Brockman; David M Knipe
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

10.  Fusion to C3d enhances the immunogenicity of the E2 glycoprotein of type 2 bovine viral diarrhea virus.

Authors:  Lingshu Wang; J Oriol Sunyer; Leonard J Bello
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.